FY2026 Earnings Estimate for Q32 Bio Issued By HC Wainwright

Q32 Bio Inc. (NASDAQ:QTTB) – Research analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for Q32 Bio in a research note issued on Tuesday, March 10th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($2.21) per share for the year, up from their previous forecast of ($2.53). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share. HC Wainwright also issued estimates for Q32 Bio’s FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($1.86) EPS, FY2029 earnings at $0.16 EPS and FY2030 earnings at $0.41 EPS.

Q32 Bio (NASDAQ:QTTB) last posted its quarterly earnings data on Tuesday, March 10th. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of ($1.06) by $4.71. The firm had revenue of $53.74 million during the quarter.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $13.00.

Q32 Bio Stock Up 1.9%

QTTB stock opened at $7.04 on Thursday. The company has a market cap of $86.59 million, a price-to-earnings ratio of 3.06 and a beta of 0.14. The company has a fifty day moving average price of $4.22 and a 200 day moving average price of $3.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.85 and a quick ratio of 4.57. Q32 Bio has a 12 month low of $1.35 and a 12 month high of $7.65.

Hedge Funds Weigh In On Q32 Bio

Institutional investors have recently bought and sold shares of the company. Opaleye Management Inc. acquired a new stake in shares of Q32 Bio in the 4th quarter worth $708,000. Geode Capital Management LLC increased its stake in shares of Q32 Bio by 19.9% during the fourth quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock worth $352,000 after acquiring an additional 17,617 shares during the period. Renaissance Technologies LLC increased its stake in shares of Q32 Bio by 110.6% during the fourth quarter. Renaissance Technologies LLC now owns 99,600 shares of the company’s stock worth $331,000 after acquiring an additional 52,300 shares during the period. Jane Street Group LLC purchased a new position in Q32 Bio during the second quarter worth about $69,000. Finally, Goldman Sachs Group Inc. raised its holdings in Q32 Bio by 140.9% during the first quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock worth $73,000 after purchasing an additional 25,953 shares in the last quarter. 31.32% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Jodie Pope Morrison sold 9,896 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $4.51, for a total value of $44,630.96. Following the transaction, the chief executive officer owned 89,104 shares of the company’s stock, valued at approximately $401,859.04. The trade was a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 16,706 shares of company stock valued at $75,344 over the last quarter. Insiders own 40.00% of the company’s stock.

Q32 Bio News Summary

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright raised its FY2026–FY2030 EPS outlook (cuts to losses in FY2026–FY2028 and upgrades to profitability in FY2029–FY2030) and reiterated a “Buy” rating with a $13 price target — a clear positive catalyst that supports a higher stock valuation and likely underpins today’s gains.
• Neutral Sentiment: The same HC Wainwright note includes quarterly 2026 EPS forecasts showing continued near-term losses (Q1–Q4 2026 at roughly ($0.52)–($0.59) per quarter), highlighting that operational profitability remains a multi-quarter challenge despite improved long-term outlook.
• Negative Sentiment: Q32 faces governance and reputational risk after a 2025 stock-option repricing that may increase compensation costs and attract shareholder scrutiny — a potential headwind for margins and investor sentiment. Q32 Bio Faces Governance Backlash and Rising Costs After 2025 Stock Option Repricing

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.